Clinical Trials Browser

Pdgfra-Associated Chronic Eosinophilic Leukemia, Congenital Abnormalities, Immunoglobulin Light-chain Amyloidosis, Blast Crisis, Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Leukemia, Hairy Cell, Leukemia, Mast-Cell, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Sezary Syndrome, Thrombocythemia, Essential, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Central Nervous System Neoplasms, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Lymphoma, Extranodal NK-T-Cell, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis, Intraocular Lymphoma

NCT07032129 2025-06-22

BAH2573

Phase 1/2 Recruiting

60 enrolled

Plasma cell

Autoimmune Diseases, Multiple Myeloma, Neoplasms, Plasma Cell

NCT06313502 2025-06-15

High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders

Phase 1 Recruiting

18 enrolled

Plasma cell

Neoplasms, Plasma Cell

NCT06863584 2025-03-07

SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II Trial

Phase 2 Recruiting

41 enrolled

Plasma cell

Neoplasms, Plasma Cell

NCT04271644 2025-02-25

BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

Phase 1/2 Recruiting

80 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04776330 2025-02-25

a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

Phase 1/2 Recruiting

80 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05597345 2025-02-10

Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

Phase 2 Recruiting

15 enrolled

Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma, Neoplasms, Plasma Cell

NCT06644443 2024-10-16

BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma

Phase 1/2 Recruiting

10 enrolled

LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT06430736 2024-07-08

PRONTO

Phase 2 Recruiting

100 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Neoplasms, Plasma Cell

NCT03832127 2024-06-14

Myelofludate

Phase 1 Recruiting

35 enrolled

Plasma cell

Neoplasms, Plasma Cell

NCT05678621 2024-04-19

RATIONALISE

Phase 2/3 Recruiting

300 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Agammaglobulinemia, Infections, Leukemia, Lymphoma, Neoplasms, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT05573802 2023-10-24

A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma

Phase 1/2 Recruiting

36 enrolled

Plasma cell

Blood Protein Disorders, Corneal Diseases, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias, Neoplasms, Plasma Cell

NCT05528887 2022-09-06

Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies

Phase 1 Recruiting

10 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Hematologic Neoplasms, Neoplasms, Plasma Cell

Clinical Trials

REALIZE

Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma

EASE

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma

Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders

Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)

HEME Home Transfusion Program

Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant

A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma

A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

BAH2573

High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders

SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II Trial

BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma

PRONTO

Myelofludate

RATIONALISE

A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma

Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies